New chief medical officer at Clavis Pharma
This article was originally published in Scrip
Clavis Pharma (Norway) has appointed Dr Athos Gianella-Borradori chief medical officer. Dr Gianella-Borradori is an onco-haematologist and drug developer, having spent the past 20 years in industry, focused on translational research and on the clinical development of anticancer agents. During this career, he has held managerial and senior clinical R&D roles at Novartis, Crucell, Bavarian Nordic, Cyclacel and, for the last five years, at Serono (later at Merck Serono). Dr Gianella-Borradori's primary role at Clavis will be to drive the clinical development of, elacytarabine, which is in Phase III for patients with acute myeloid leukaemia, and of CP-4126 in partnership with Clovis Oncology, which is in Phase II development for patients with pancreatic cancer.
You may also be interested in...
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.